GT Biopharma (GTBP) had the highest return in 2015 by a US stock in the Biotechnology Industry, returning 9,042.9%.
| ASSET | YEAR | % RETURN |
|---|---|---|
GT Biopharma (GTBP) | 2015 | 9,042.86% |
MDxHealth SA ADR (MDXH) | 2015 | 633.33% |
Anavex Life Sciences (AVXL) | 2015 | 632.89% |
Exelixis (EXEL) | 2015 | 283.67% |
Galapagos NV ADR (GLPG) | 2015 | 239.71% |
Prothena (PRTA) | 2015 | 224.33% |
Sarepta Therapeutics (SRPT) | 2015 | 164.61% |
Heron Therapeuti (HRTX) | 2015 | 162.28% |
Ultragenyx (RARE) | 2015 | 152.54% |
Neurocrine Biosciences (NBIX) | 2015 | 150.42% |
Genmab A-S (GMAB) | 2015 | 123.37% |
Marker Therapeutics (MRKR) | 2015 | 114.29% |
Lexicon Pharmaceuticals (LXRX) | 2015 | 104.45% |
Xenetic Biosciences (XBIO) | 2015 | 104% |
Ligand Pharmaceuticals (LGND) | 2015 | 102.01% |
Amarin (AMRN) | 2015 | 92.86% |
Dyadic International (DYAI) | 2015 | 92.55% |
Curis (CRIS) | 2015 | 91.45% |
DiaMedica Therapeutics (DMAC) | 2015 | 90% |
Matinas BioPharma (MTNB) | 2015 | 88.89% |
Rocket Pharmaceuticals (RCKT) | 2015 | 85.74% |
Lexaria Bioscience (LEXX) | 2015 | 85.66% |
Halozyme Therapeutics (HALO) | 2015 | 77.38% |
Neurogene (NGNE) | 2015 | 75.01% |
Oragenics (OGEN) | 2015 | 70.45% |